Autoinflammatory syndromes: Fever is not always a sign of infection

Cleveland Clinic Journal of Medicine

Volumn 79, Issue 8, 2012, Pages 569-581

  Zeft, Andrew S ^a   Spalding, Steven J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; COLCHICINE; TUBULIN MODULATOR;

ADULT; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HEREDITARY PERIODIC FEVER; HUMAN; MALE; MEVALONATE KINASE DEFICIENCY; MUTATION; PATHOLOGY; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RISK; SYNDROME;

COLCHICINE; DIAGNOSIS, DIFFERENTIAL; GOUT SUPPRESSANTS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; MALE; MEVALONATE KINASE DEFICIENCY; MUTATION; PROGNOSIS; QUALITY OF LIFE; RISK; SYNDROME; TUBULIN MODULATORS; YOUNG ADULT;

EID: 84866323465     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79a.11184     Document Type: Review

References (74)

1. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of prolL-beta. Mol Cell 2002; 10:417-426. (Pubitemid 35007355)
2. Siegal S. Benign paroxysmal peritonitis. Gastroenterology 1949; 12:234-247.
3. International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90:797-807.
4. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17:25-31.
5. Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 2009; 60:1862-1866.
6. Cattan D. Familial Mediterranean fever: is low mortality from tuberculosis a specific advantage for MEFV mutations carriers? Mortality from tuberculosis among Muslims, Jewish, French, Italian and Maltese patients in Tunis (Tunisia) in the first half of the 20th century. Clin Exp Rheumatol 2003; 21(suppl 30):S53-S54. (Pubitemid 37193100)
7. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009; 27:621-668.
8. Fidder H, Chowers Y, Ackerman Z, et al. The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease. Am J Gastroenterol 2005; 100:338-343. (Pubitemid 40314518)
9. Shinar Y, Livneh A, Villa Y, et al. Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. Genes Immun 2003; 4:197-203. (Pubitemid 38967597)
10. Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 2004; 5:4.
11. Mimouni A, Magal N, Stoffman N, et al. Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 2000; 105:E70.
12. Touitou I, Sarkisian T, Medlej-Hashim M, et al; International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007; 56:1706- 1712.
13. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287:1302.
14. Wolff SM, Dinarello CA, Dale DC, Goldfinger SE, Alling DW. Colchicine therapy of familial Mediterranean fever. Trans Assoc Am Physicians 1974; 87:186-194.
15. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974; 291:934-937.
16. Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin Arthritis Rheum 1991; 21:143-155.
17. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004; 33:273-282. (Pubitemid 38280826)
18. Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF - definition, causes and suggested solutions. Clin Exp Rheumatol 2008; 26(suppl 50):S49-S51.
19. Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum 2009; 61:1447-1453.
20. van der Meer JW, Vossen JM, Radl J, et al. Hyperimmunoglobulinaemia Dand periodic fever: a new syndrome. Lancet 1984; 1:1087- 1090. (Pubitemid 14100804)
21. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-lgD and periodic fever syndrome. International Hyper-lg D Study Group. Nat Genet 1999; 22:178-181. (Pubitemid 29264814)
22. Houten SM, Frenkel J, Kuis W, Wanders RJ, Poll-The BT, Waterham HR. Molecular basis of classical mevalonic aciduria and the hyperim- munoglobulinaemia D and periodic fever syndrome: high frequency of 3 mutations in the mevalonate kinase gene. J Inherit Metab Dis 2000; 23:367-370. (Pubitemid 30364773)
23. Poll-The BT, Frenkel J, Houten SM, et al. Mevalonic aciduria in 12 unrelated patients with hyperimmunoglobulinaemia D and periodic fever syndrome. J inherit Metab Dis 2000; 23:363-366. (Pubitemid 30364772)
24. Mandey SH, Kuijk LM, Frenkel J, Waterham HR. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006; 54:3690-3695.
25. van der Hilst JC, Frenkel J. Hyperimmunoglobulin D syndrome in childhood. Curr Rheumatol Rep 2010; 12:101-107.
26. Simon A, Cuisset L, Vincent MF, et al. Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool. Ann Intern Med 2001; 135:338-343. (Pubitemid 32825497)
27. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley Rl, Kastner DL Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003; 48:2645-2651. (Pubitemid 37129442)
28. Korppi M, Van Gijn ME, Antila K. Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatr 2011; 100:21-25.
29. Rigante D, Ansuini V, Bertoni B, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006; 27:97-100. (Pubitemid 44655757)
30. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 2011; 70:2155-2158.
31. van der Hilst JC, Bodar EJ, Barron KS, et al; International HIDS Study Group. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87:301-310.
32. Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ. Familial Hibernian fever. Q J Med 1982; 51:469-480. (Pubitemid 13224401)
33. Mulley J, Saar K, Hewitt G, et al. Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 1998; 62:884-889. (Pubitemid 28194331)
34. McDermott MF, Ogunkolade BW, McDermott EM, et al. Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 1998;62:1446-1451. (Pubitemid 28307114)
35. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-144. (Pubitemid 29165896)
36. Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301-314. (Pubitemid 32695203)
37. Dodé C, André M, Bienvenu T, et al; French Heraditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46:2181-2188.
38. Aganna E, Hammond L, Hawkins PN, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003; 48:2632-2644. (Pubitemid 37129441)
39. Ravet N, Rouaghe S, Dodé C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65:1158-1162. (Pubitemid 44277389)
40. Dieudé P, Goossens M, Cornélis F, Michou L, Bardin T, Tchernitchko DO; European Consortium on Rheumatoid Arthritis Families. The TNFRSF1A R92Q mutation is frequent in rheumatoid arthritis but shows no evidence for association or linkage with the disease. Ann Rheum Dis 2007; 66:1113-1115. (Pubitemid 47122329)
41. Ida H, Kawasaki E, Miyashrta T, et al. A novel mutation (T611) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptorassociated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43:1292-1299. (Pubitemid 39359307)
42. Kümpfel T, Hoffmann LA, Pellkofer H, et al. Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. Neurology 2008; 71:1812-1820.
43. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81:349-368.
44. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003; 42:235-239. (Pubitemid 36305608)
45. Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012;64:908-913.
46. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000; 343:1044-1045.
47. Simsek I, Kaya A, Erdem H, Pay S, Yenicesu M, Dinc A. No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. J Nephrol 2010; 23:119-123.
48. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301-315.
49. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46:2445-2452.
50. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-3348. (Pubitemid 35453546)
51. Tanaka N, Izawa K, Saito MK, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 2011; 63:3625-3632.
52. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443-2652.
53. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-2425.
54. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011; 63:840-849.
55. Prieur AM, Griscelli C, Lampert F, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987; 66:57-68.
56. Jéru I, Duquesnoy P, Fernandes-Alnemri T, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A 2008; 105:1614-1619. (Pubitemid 351346563)
57. Borghini S, Tassi S, Chiesa S, et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 2011; 63:830-839.
58. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-2437.
59. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360:2438-2444.
60. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11:961-969. (Pubitemid 34449783)
61. Ferguson PJ, Chen S, Tayeh MK, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005; 42:551-557. (Pubitemid 40993830)
62. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29:19-20. (Pubitemid 32801800)
63. Padeh S, Stoffman N, Berkun Y. Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults. Isr Med Assoc J 2008; 10:358-360. (Pubitemid 351902935)
64. Cochard M, Clet J, Le L, et al. PFAPA syndrome is not a sporadic disease. Rheumatology (Oxford) 2010; 49:1984-1987.
65. Stojanov S, Lapidus S, Chitkara P, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A 2011; 108:7148-7153.
66. Thomas KT, Feder HM Jr, Lawton AR, Edwards KM. Periodic fever syndrome in children. J Pediatr 1999; 135:15-21. (Pubitemid 30180556)
67. Feder HM Jr. Cimetidine treatment for periodic fever associated with aphthous stomatitis, pharyngitis and cervical adenitis. Pediatr Infect Dis J 1992;11:318-321.
68. Tasher D, Stein M, Dalal I, Somekh E. Colchicine prophylaxis for frequent periodic fever, aphthous stomatitis, pharyngitis and adenitis episodes. Acta Paediatr 2008; 97:1090-1092.
69. Pillet P, Ansoborlo S, Carrère A, Perel Y, Guillard JM. [(P)FAPA syndrome: value of cimetidine]. In French. Arch Pediatr 2000; 7:54-57. (Pubitemid 30048472)
70. Kallinich T, Haffner D, Rudolph B, et al. "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Ann Rheum Dis 2006; 65:958-960.
71. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43:227-253.
72. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009; 124:1141- 1149.
73. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241. (Pubitemid 43372104)
74. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1B in type 2 diabetes. Nat Immunol 2010;11:897-904.